What is the surgical sympathectomy (thoracoscopic) for a patient with coronary artery spasm refractory to maximal calcium‑channel blockers, nitrates, and alpha‑blockers?

Surgical Sympathectomy for Refractory Coronary Artery Spasm

For patients with coronary artery spasm refractory to maximal doses of calcium-channel blockers, nitrates, and alpha-blockers, thoracoscopic sympathectomy is a reasonable therapeutic option that can prevent recurrent vasospasm and reduce major adverse cardiac events. 1

Evidence-Based Recommendation

The most authoritative guideline evidence explicitly states that "in the rare patients who are refractory to maximally tolerated doses of calcium-channel blockers, sympathectomy is a therapeutic option" for vasospastic angina 1. Multiple ACC/AHA guidelines acknowledge that cardiac denervation has been used in patients refractory to standard medication, though they note the benefit as "marginal" in older literature 2.

However, the most recent and highest-quality research evidence contradicts this conservative stance. A 2019 randomized controlled trial 3 demonstrated that sympathectomy significantly reduced major adverse cardiac events (MACE) compared to conventional treatment in refractory coronary artery spasm patients:

• MACE incidence: 16.22% (sympathectomy) vs 61.90% (conventional treatment), P=0.0001
• All-cause death: 0% (sympathectomy) vs 14.29% (conventional treatment), P=0.0272
• 24-month follow-up showed sustained benefit with significant reduction in vasospasm recurrence

Surgical Technique

The procedure involves bilateral thoracoscopic sympathectomy, typically resecting T2-T5 ganglia 4, 5. The surgery is:

• Performed under general anesthesia
• Minimally invasive via video-assisted thoracoscopy
• Well-tolerated even in critically ill patients 4, 6, 7
• Can be done as staged bilateral procedures or simultaneously

Clinical Algorithm for Patient Selection

Consider sympathectomy when:

1. Documented coronary artery spasm (ST-segment elevation during chest pain, positive provocative testing, or angiographic visualization)
2. Failure of maximal medical therapy:
   • High-dose calcium-channel blockers (verapamil 240-480 mg/d, diltiazem 180-360 mg/d, or nifedipine 60-120 mg/d)
   • Long-acting nitrates
   • Alpha-receptor blockers
   • Combination therapy with multiple drug classes 8
3. Persistent symptoms causing significant morbidity or life-threatening events (cardiac arrest, sustained ventricular arrhythmias, recurrent myocardial infarction)

Proceed urgently when:

• Multiple ICD discharges from vasospasm-induced arrhythmias 9, 4
• Hemodynamic instability requiring intensive care 4, 7
• Failed attempts at weaning from cardiopulmonary bypass due to vasospasm 4

Important Caveats

Prognosis considerations: Patients with vasospastic angina and normal or near-normal coronary arteries have excellent prognosis with medical therapy alone (89-97% 5-year survival) 8. Therefore, sympathectomy should be reserved for truly refractory cases where medical therapy has definitively failed.

Potential complications: While rare, refractory spasm can occur even after sympathectomy. One historical case reported fatal refractory right coronary artery spasm 2 hours after complete denervation by plexectomy 10. Modern series show better outcomes with standardized bilateral T2-T5 resection 3, 7.

Alternative considerations before surgery:

• Verify medication compliance and adequate dosing
• Rule out provocative factors (cocaine use, hyperthyroidism) 1, 2
• Consider provocative testing to confirm diagnosis if not already done 8
• Ensure beta-blockers have been discontinued (they can precipitate spasm) 1

Strength of Evidence

The 2019 RCT 3 provides the strongest evidence for sympathectomy in this population, showing dramatic reduction in both morbidity and mortality. Recent case reports 9, 4 from 2021-2025 demonstrate successful application in real-world refractory cases. The procedure has evolved from "marginal benefit" in older guidelines to a definitive treatment option with robust outcomes data.

Bottom line: Thoracoscopic sympathectomy should be offered to patients with refractory coronary artery spasm who have failed maximal medical therapy, as it significantly reduces MACE and mortality compared to continued conservative management.